Ignite Creation Date:
2025-12-24 @ 9:49 PM
Ignite Modification Date:
2026-02-01 @ 4:56 AM
Study NCT ID:
NCT04836832
Status:
WITHDRAWN
Last Update Posted:
2022-06-07
First Post:
2021-03-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Sponsor:
Narendranath Epperla
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Follicular Lymphoma | View |
| None | Recurrent Marginal Zone Lymphoma | View |
| None | Recurrent Nodal Marginal Zone Lymphoma | View |
| None | Recurrent Splenic Marginal Zone Lymphoma | View |
| None | Refractory Follicular Lymphoma | View |
| None | Refractory Indolent Non-Hodgkin Lymphoma | View |
| None | Refractory Marginal Zone Lymphoma | View |
| None | Refractory Nodal Marginal Zone Lymphoma | View |
| None | Refractory Splenic Marginal Zone Lymphoma | View |
Keywords: